On Tuesday, Etsy Inc (NASDAQ:ETSY)’s shares inclined 12.04% to $16.01.
Etsy, Inc. (ETSY), a marketplace where people around the world connect, both online and offline, to make, sell and buy unique goods, declared financial results for its second quarter 2015, ended June 30, 2015.
Second Quarter 2015 Operational Highlights
GMS was $546.2 million, up 24.6% contrast with the second quarter of 2014. Growth in GMS was driven by 24.6% year-over-year growth in active sellers and 31.6% year-over-year growth in active buyers. We continued to make progress in narrowing the gap between mobile visits and mobile GMS as a result of strong year-over-year GMS growth on our mobile app platform. Etsy has rapidly become a mobile-first company; percent mobile visits was about 60% contrast with about 53% in the second quarter of 2014 and percent mobile GMS was about 43% contrast with about 36% in the second quarter of 2014. Mobile visits also continued to grow faster than desktop visits.
Sealed Air Corp (NYSE:SEE)’s shares dropped -1.27% to $54.60.
Sealed Air (SEE) declared the acquisition of B+ Equipment, a company headquartered in France that designs, manufactures and services automated packaging equipment for order fulfillment operations.
The acquisition comprises B+’s proprietary flagship I-Pack® system and the newly introduced e-Cube™ system, both of which provide intelligent, high-velocity fulfillment – which is especially impactful in the area of e-commerce. Sealed Air has had a long-standing relationship with B+, as the exclusive licensee of the I-Pack® system in North America, Australia, and New Zealand for more than five years.
Sealed Air Corporation provides food safety and security, facility hygiene, and product protection solutions worldwide. The company’s Food Care segment offers integrated system solutions that incorporate equipment systems into customers operations; and packaging equipment systems that incorporate various options for loading, filling and dispensing, and retort and aseptic processing conditions. It also provides graphic design, printing, training, field quality assurance, and remote diagnostics services; and clean-in-place and open plant systems that integrate cleaning chemicals, lubricants, floor care equipment, and cleaning tools. This segment offers its products under the Cryovac, Diversey, Cryovac Grip & Tear, Darfresh, Cryovac Mirabella, Simple Steps, Secure Check, and Enduro Power brands.
At the end of Tuesday’s trade, bluebird bio Inc (NASDAQ:BLUE)‘s shares dipped -2.40% to $135.89.
bluebird bio, Inc. ( BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, recently stated business highlights and financial results for the second quarter ended June 30, 2015.
Recent Highlights
SICKLE CELL DISEASE (SCD) AND BETA-THALASSEMIA DATA PRESENTATION AT THE 20TH CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION – Presented positive data from two patients with beta-thalassemia major and the first patient with severe sickle cell disease ever treated with our LentiGlobin BB305 product candidate. As of May 2015, Subjects 1201 and 1202 with beta-thalassemia major remained transfusion-independent for 16 and 14 months, respectively. Subject 1204 with severe SCD demonstrated increasing HbAT87Q production at six months’ follow-up and was free of transfusions for more than three months. At the six-month visit post-drug product infusion, the proportion of anti-sickling hemoglobin (HbAT87Q + HbF) in the patient with SCD accounted for 45 percent of all hemoglobin production. As of May 2015, the patient with SCD had no hospitalizations for sickle cell complications post-transplant, despite weaning of transfusions. LentiGlobin BB305 was well-tolerated, with no drug product-related adverse events observed as of the May 2015 data cut-off.
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic and rare diseases. Its advanced product candidate is Lenti-D, which is in phase II/III clinical studies for the treatment of childhood cerebral adrenoleukodystrophy, a rare, hereditary neurological disorder affecting young boys; and LentiGlobin that is in phase I/II clinical studies for the treatment of beta-thalassemia major and severe sickle cell disease (SCD) in France, in addition to a phase I study in the United States for the treatment of severe SCD.
HORSEHEAD HOLDING CORP. (NASDAQ:ZINC), ended its Tuesday’s trading session with -3.79% loss, and closed at $9.13.
Horsehead Holding Corp. ( ZINC) stated a merged net loss of $3.6 million, or $(0.06) per diluted share, for the second quarter of 2015 contrast to a merged net loss of $5.1 million, or $(0.10) per diluted share, for the second quarter of 2014. Results for the quarter, adjusted to exclude favorable non-cash adjustments associated with hedges, was a merged net loss of $12.4 million, or $(0.22) per diluted share, contrast to a merged net loss on the same basis of $3.2 million for the second quarter of 2014, or $(0.06) per diluted share.
Second Quarter Highlights
Contrast to the same quarter last year:
- Zinc finished product and calcine shipments, on a zinc contained basis, reduced 8,633 tons, or 15.7%, to 46,418 tons for the quarter, comprised of 29,017 zinc tons of finished products and 17,401 zinc tons in calcine.
- EAF dust receipts reduced 10.7% to 134,511 tons, primarily reflecting reduced industry steel production.
- The LME zinc price averaged $0.99/lb for the second quarter of 2015 and $0.94/lb for the second quarter of 2014. The LME nickel price averaged $5.90/lb for the second quarter of 2015 contrast to $8.38/lb for the second quarter of 2014.
Horsehead Holding Corp., together with its auxiliaries, produces and sells zinc and nickel-based products primarily in the United States and Canada. The company operates through three segments: Horsehead, Zochem, and INMETCO. The Horsehead segment processes electric arc furnace dust and other zinc-bearing material to produce and sell zinc and other metals. The Zochem segment produces and sells zinc oxide.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
